Brief: Jade Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Update
06/03/2026 12:27
March 6 (Reuters) - Jade Biosciences Inc JBIO.O: JADE BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE JADE BIOSCIENCES INC: $336 MILLION OF CASH, CASH EQUIVALENTS, AND INVESTMENTS AS OF DECEMBER 31ST, 2025 EXPECTED TO PROVIDE RUNWAY INTO H1 2028 JADE BIOSCIENCES INC: EXPECTS TO INITIATE A PHASE 2 CLINICAL TRIAL IN PATIENTS WITH IGAN MID-2026, WITH PRELIMINARY DATA ANTICIPATED IN 2027 Source text: ID:nGNX9mKZKs Further company coverage: JBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million